Project Grant HT94252510466
Award Date
7/1/25
Completion Date
6/30/29
Dollars Obligated
$11M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40526, USA
Similar Awards
This Cooperative Agreement award of $638,820 from the Defense Health Agency supports an mRNA multivalent approach to develop an innovative malaria vaccine. The project, funded through the Military Medical Research and Development program (CFDA 12.420), aims to broaden the immune targets against malaria infection by including both pre-erythrocytic-stage antigens and mosquito saliva antigens. The Geneva Foundation, a non-profit research organization, will conduct this research over a 3-year period...
The Project Grant award for $897,448.00, awarded on June 1, 2024 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports Oregon Health & Science University's development of "NEXT-GENERATION ELQS FOR LONG-TERM PROTECTION AGAINST MALARIA." This research initiative aims to advance novel treatments and protective measures against malaria, a key focus area for the Defense Health Agency's military medical research initiatives....
This $2,024,907.00 Cooperative Agreement award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the "STRUCTURE-GUIDED DEVELOPMENT OF POTENT PFPKG INHIBITORS FOR MALARIA CHEMOPROTECTION" project led by Rutgers, The State University of New Jersey (Rutgers), doing business as RBHS-School of Nursing. The project aims to conduct research and development to create new malaria prevention treatments. As the prime awardee, Rutgers...
The Department of the Army Medical Command awarded a $5,753,844 Project Grant under the Military Medical Research and Development federal grant program (CFDA 12.420) to the Portland VA Research Foundation, Inc. for the period of July 1, 2022 to June 30, 2026. The grant will support the preclinical development of novel liver-stage active antimalarial drugs with radical cure potential. Through innovative research, the goal is to transform healthcare for service members and the public by...
This Cooperative Agreement, awarded by the Defense Health Agency, provides $568,275 in funding to Conserv Bioscience LIMITED, a foreign-owned for-profit organization, to develop an mRNA multivalent approach including pre-erythrocytic-stage antigens and mosquito saliva antigens to broaden the immune targets against malaria infection. The funding is provided through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical...
The University of Queensland in Australia was awarded a $2,383,881 Project Grant from the Department of the Army Medical Command on September 15, 2022 to complete work by September 14, 2026. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform health care for service members and the public through innovative and impactful research, as well as investigate medical solutions for the...
The Department of the Army Medical Command has awarded a $745,381 Project Grant through the Military Medical Research and Development (CFDA 12.420) federal grant program to The University of Kentucky Research Foundation. The grant, entitled "ENHANCING THE THERAPEUTIC POTENTIAL OF NANOPARTICLE-MEDIATED IMMUNOTHERAPEUTICS FOR SPINAL TRAUMA," supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The...
This $384,063 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research at The Pennsylvania State University to directly genetically modify Plasmodium sporozoites using mRNA/lipid nanoparticles. The two-year effort, running from February 2025 to January 2027, aims to advance transformative healthcare solutions for military service members and the broader public by exploring innovative approaches to disease...
This federal Project Grant award of $400,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, with a performance period from October 1, 2024 to September 30, 2026. The award supports research by the University of Maryland, Baltimore to develop "drug conjugates of modified LGR4/5/6 ligands for cancer treatment." The university, as the prime awardee, has extensive expertise in biomedical research, clinical trials, and...
The federal Project Grant award, ID HT94252410512, in the amount of $1,008,313.00, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The grant was awarded to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution, to support advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader...